Advances in Parasite Genomics

Following the SARS-CoV-2 pandemic, several clinical trials have been approved for the investigation of the possible use of mAbs, supporting the potential of this technology as a therapeutic approach for infectious diseases. The first monoclonal antibody (mAb), Muromonab CD3, was introduced for the prevention of kidney transplant rejection more than 30 years ago; since then more than 100 mAbs have been approved for therapeutic purposes. Nonetheless, only four mAbs are currently employed for infectious diseases: Palivizumab, for the prevention of respiratory syncytial virus (RSV) infections, Raxibacumab and Obiltoxaximab, for the prophylaxis and treatment against anthrax toxin and Bezlotoxumab, for the prevention of Clostridium difficile recurrence. Protozoan infections are often neglected diseases for which effective and safe chemotherapies are generally missing. In this context, drug resistance and drug toxicity are two crucial problems. The recent advances in bioinformatics, parasite genomics, and biochemistry methodologies are contributing to better understand parasite biology, which is essential to guide the development of new therapies. In this review, we present the efforts that are being made in the evaluation of mAbs for the prevention or treatment of leishmaniasis, Chagas disease, malaria, and toxoplasmosis. Particular emphasis will be placed on the potential strengths and weaknesses of biological treatments in the control of these protozoan diseases that are still affecting hundreds of thousands of people worldwide.

Download Full-text

Parasite genomics

Molecular Medical Parasitology ◽

10.1016/b978-012473346-6/50002-8 ◽

2003 ◽

pp. 3-I

Author(s):

Mark Blaxter

Keyword(s):

Parasite Genomics

Download Full-text

Realizing the promise of parasite genomics

Trends in Parasitology ◽

10.1016/j.pt.2014.04.008 ◽

2014 ◽

Vol 30 (7) ◽

pp. 321-323 ◽

Cited By ~ 10

Author(s):

James D. Wasmuth

Keyword(s):

Parasite Genomics

Download Full-text

Parasite genomics: current status and future prospects

Current Opinion in Immunology ◽

10.1016/s0952-7915(00)00233-8 ◽

2001 ◽

Vol 13 (4) ◽

pp. 395-402 ◽

Cited By ~ 14

Author(s):

Rick L Tarleton ◽

Jessica Kissinger

Keyword(s):

Current Status ◽

Future Prospects ◽

Parasite Genomics

Download Full-text

Progress in Parasite Genomics and Its Application to Current Challenges in Malaria Control

10.5772/intechopen.96530 ◽

2021 ◽

Author(s):

Cheikh Cambel Dieng ◽

Colby T. Ford ◽

Jennifer Huynh ◽

Linda E. Amoah ◽

Yaw A. Afrane ◽

...

Keyword(s):

Malaria Control ◽

Vaccine Development ◽

Diagnostic Testing ◽

Current Control ◽

Control Mechanisms ◽

African Countries ◽

Malaria Vaccines ◽

Antimalarial Resistance ◽

Genetic Mechanisms ◽

Parasite Genomics

A wide deployment of malaria control tools have significantly reduced malaria morbidity and mortality across Africa. However, in the last five to seven years, there has been a resurgence of malaria in several African countries, raising the questions of whether and why current control mechanisms are failing. Since the first Plasmodium falciparum reference genome was published in 2002, few thousands more representing a broad range of geographical isolates have been sequenced. These advances in parasite genomics have improved our understanding of mutational changes, molecular structure, and genetic mechanisms associated with diagnostic testing, antimalarial resistance, and preventive measures such as vaccine development. In this chapter, we summarize the current progress on: (1) genomic characteristics of P. falciparum; (2) novel biomarkers and revolutionary techniques for diagnosing malaria infections; and (3) current vaccine targets and challenges for developing efficacious and long-lasting malaria vaccines.

Download Full-text